TIGER

A Randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high dose chemotherapy using mobilizing paclitaxel followed by High-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumours

III

interventionell

International

Cisplatin, Ifosfamid, Paclitaxel, Carboplatin, Etoposid

Status: In Rekrutierung

Zeitraum

2016

2022

Zentren

11

11

Keine Zentren gesucht

Patienten

75

59

19.04.2022

Klinische Settings

2nd line

palliativ

Beteiligte

AIO-Arbeitsgruppen

Sponsor

Alliance for Clinical Trials in Oncology

Kooperierende Fachgesellschaft(en)

National Cancer Institute (NCI) European Organisation for Research and Treatment of Cancer - EORTC Movember Foundation Institute of Cancer Research (ICR), United Kingdom Cancer Research UK UNICANCER Irish Group CTI

Förderer

Deutsche Krebshilfe

Identifier

AIO-GC-0416/ass

AIO-GC-0416/ass

A031102,U10CA180821 (U.S. NIH Grant/Contract),NCI-2014-01696 (Registry Identifier: NCI Clinical Trial Reporting Program)

Kontakt

Leitung

Prof. Dr. med. Marcus Hentrich

Ansprechpartner*in

Susanne Harnisch / Kerstin Balthasar
E-Mail susanne.harnisch@kks.uni-marburg.de